<scp>ITGBL1</scp> promotes anoikis resistance and metastasis in human gastric cancer via the <scp>AKT</scp>/<scp>FBLN2</scp> axis

Kanger Shen, Wei Xia, Kun Wang, Juntao Li, Wei Xu, Haoran Liu, Kexi Yang, Jinghan Zhu, Jiayu Wang, Qinhua Xi, Tongguo Shi, Rui LiJournal of Cellular and Molecular Medicine 2024 · DOI

TL;DR

This study uncovers a novel mechanism by which Integrin beta-like 1 (ITGBL1) drives gastric cancer (GC) metastasis. ITGBL1 promotes anoikis resistance (the ability of cancer cells to survive detachment) and metastasis by suppressing Fibulin-2 (FBLN2) expression via the AKT signaling pathway, leading to poorer patient prognosis.

What Problem Does This Paper Address?

Gastric cancer (GC) remains a significant global health challenge, with distant metastasis being a primary driver of poor patient outcomes. A key step in metastasis is the ability of cancer cells to survive detachment from the extracellular matrix, a process known as anoikis. While anoikis resistance is crucial for metastasis, the precise molecular mechanisms governing it in GC are not fully understood. This paper aims to elucidate the role of ITGBL1, a protein previously linked to cancer progression, in promoting anoikis resistance and metastasis in GC, and to uncover the underlying molecular pathways.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics Analysis: They utilized TCGA and GEPIA databases to analyze ITGBL1 expression in GC tissues and its correlation with clinical stages and patient prognosis. Weighted Gene Coexpression Network Analysis (WGCNA) and machine learning techniques (LASSO, SVM) were used to identify potential downstream targets of ITGBL1.
  • Cell Culture and Manipulation: Standard GC cell lines (AGS, HGC27, MKN28, MKN45) and a normal gastric mucosal cell line (GES-1) were cultured. Anoikis-resistant (AR) GC cell models were established through forced suspension culture. Lentiviral transduction was used to overexpress ITGBL1, while siRNAs were used to knockdown ITGBL1 and FBLN2. Plasmid transfection was used to overexpress FBLN2.
  • In Vitro Assays:
    • Western Blotting: To assess protein expression levels of ITGBL1, FBLN2, cleaved PARP1, cleaved Caspase9, cleaved Caspase3, BAX, Bcl-2, AKT, and phosphorylated AKT (P-AKT).
  • Apoptosis Assays (Flow Cytometry): To quantify the rate of apoptosis in detached cells.
  • Transwell Migration and Invasion Assays: To measure the ability of cancer cells to move and penetrate through a matrix.
  • In Vivo Studies: A mouse lung metastasis model was established by injecting AR-GC cells via tail vein. Lung tissues were analyzed for metastatic nodules and protein expression via Hematoxylin-Eosin (H&E) staining and immunohistochemistry (IHC).
  • Pharmacological Inhibition: The AKT pathway inhibitor perifosine and activator SC79 were used to investigate the role of AKT signaling.

Datasets

  • TCGA (The Cancer Genome Atlas) database: Used for analyzing ITGBL1 mRNA expression in GC tissues and its correlation with clinical stage.
  • GEPIA (Gene Expression Profiling Interactive Analysis) database: Used for analyzing ITGBL1 mRNA expression and its correlation with overall and disease-free survival in GC patients.
  • Human GC patient tissue samples: Used for immunohistochemical analysis of ITGBL1 and FBLN2 protein expression.

Key Insights and Ideas

  • ITGBL1 as a Driver of Anoikis Resistance: The study provides strong evidence that ITGBL1 actively promotes the survival of GC cells when they detach from their matrix, a critical step for metastasis. This is a significant finding as it directly links ITGBL1 to a fundamental requirement for cancer spread.
  • The AKT/FBLN2 Axis as the Key Mediator: The research pinpoints the AKT signaling pathway and its interaction with Fibulin-2 (FBLN2) as the central mechanism through which ITGBL1 exerts its effects. This reveals a specific molecular pathway that can be targeted.
  • ITGBL1 Suppresses FBLN2: A surprising and crucial finding is that ITGBL1 negatively regulates FBLN2 expression. This is counterintuitive, as FBLN2 has been reported to have tumor-suppressive roles in some cancers. This suggests a context-dependent role for FBLN2 in GC.
  • FBLN2 Reverses ITGBL1's Effects: Overexpressing FBLN2 was shown to counteract the pro-metastatic and anoikis-resistant effects induced by ITGBL1, highlighting FBLN2's potential as a tumor suppressor in this context.
  • Clinical Relevance: The study demonstrates that high ITGBL1 expression is significantly correlated with advanced GC stages and poorer patient prognosis, and importantly, that the combination of high ITGBL1 and low FBLN2 expression is associated with the worst outcomes. This suggests ITGBL1 could be a valuable prognostic biomarker.

Key Results

  • Increased ITGBL1 in GC: ITGBL1 mRNA and protein levels were significantly elevated in GC tissues and cell lines compared to normal counterparts.
  • ITGBL1 Promotes Anoikis Resistance and Metastasis: Overexpression of ITGBL1 in AR-GC cells significantly increased anoikis resistance and enhanced migration and invasion in vitro. Knockdown of ITGBL1 had the opposite effect.
  • In Vivo Metastasis Reduction: In a mouse model, ITGBL1 knockdown significantly reduced lung metastasis. Conversely, double knockdown of ITGBL1 and FBLN2 led to increased lung metastasis compared to ITGBL1 knockdown alone.
  • FBLN2 Reversal of ITGBL1 Effects: Overexpression of FBLN2 reversed the effects of ITGBL1 overexpression on anoikis resistance and metastasis in AR-AGS cells. Similarly, FBLN2 knockdown reversed the effects of ITGBL1 knockdown in AR-MKN45 cells.
  • AKT Pathway Activation: ITGBL1 overexpression activated the AKT pathway, while its knockdown suppressed it. Inhibition of AKT with perifosine abolished ITGBL1's effects on FBLN2 expression and metastasis.
  • Prognostic Significance: High ITGBL1 expression was associated with worse overall survival in GC patients. Patients with high ITGBL1 and low FBLN2 expression had the poorest prognosis.

Limitations and Future Work

  • Mechanism of AKT Activation: While the study demonstrates that ITGBL1 activates the AKT pathway, the precise upstream mechanism by which ITGBL1 induces AKT activation remains unclear and requires further investigation.
  • Context-Dependent Role of FBLN2: The study highlights a context-dependent role for FBLN2, acting as a tumor suppressor in this GC model, which contrasts with its reported oncogenic roles in other cancers. Further research could explore the molecular basis for this difference.
  • Therapeutic Strategies: The findings suggest that targeting the ITGBL1/AKT/FBLN2 axis could be a promising therapeutic strategy for GC. Future work could focus on developing specific inhibitors for this pathway.

Summary updated

Abstract

The resistance to anoikis plays a critical role in the metastatic progression of various types of malignancies, including gastric cancer (GC). Nevertheless, the precise mechanism behind anoikis resistance is not fully understood. Here, our primary focus was to examine the function and underlying molecular mechanism of Integrin beta-like 1 (ITGBL1) in the modulation of anoikis resistance and metastasis in GC. The findings of our investigation have demonstrated that the overexpression of ITGBL1 significantly augmented the resistance of GC cells to anoikis and promoted their metastatic potential, while knockdown of ITGBL1 had a suppressive effect on both cellular processes in vitro and in vivo. Mechanistically, we proved that ITGBL1 has a role in enhancing the resistance of GC cells to anoikis and promoting metastasis through the AKT/Fibulin-2 (FBLN2) axis. The inhibition of AKT/FBLN2 signalling was able to reverse the impact of ITGBL1 on the resistance of GC cells to anoikis and their metastatic capability. Moreover, the expression levels of ITGBL1 were found to be significantly elevated in the cancerous tissues of patients diagnosed with GC, and there was a strong correlation observed between high expression levels of ITGBL1 and worse prognosis among individuals diagnosed with GC. Significantly, it was revealed that within our cohort of GC patients, individuals exhibiting elevated ITGBL1 expression and diminished FBLN2 expression experienced the worst prognosis. In conclusion, the findings of our study indicate that ITGBL1 may serve as a possible modulator of resistance to anoikis and the metastatic process in GC.
BibTeX
@article{shen2024scp,
  author = {Kanger Shen and Wei Xia and Kun Wang and Juntao Li and Wei Xu and Haoran Liu and Kexi Yang and Jinghan Zhu and Jiayu Wang and Qinhua Xi and Tongguo Shi and Rui Li},
  title = {{<scp>ITGBL1</scp> promotes anoikis resistance and metastasis in human gastric cancer via the <scp>AKT</scp>/<scp>FBLN2</scp> axis}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.18113},
}
Figure